Skip to main content
Evidence Snapshot

Tyrosine-protein kinase Mer

CHEMBL5331 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:04:52Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5331
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase Mer as ChEMBL target CHEMBL5331, mapped to UniProt Q12866. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tyrosine-protein kinase Mer
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5331
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q12866
Tyrosine-protein kinase Mer
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Tyrosine-protein kinase Mer matters

As of 2026-09-13

Tyrosine-protein kinase Mer is reviewed as Tyrosine-protein kinase Mer (UniProt Q12866); Tyrosine-protein kinase Mer shows clinical signal disease relevance led by non-small cell lung carcinoma.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 17 approved drugs, 4191 compounds, and 413 assays, with lead potency reaching pChEMBL 9.9.

Disease context
non-small cell lung carcinoma

Tyrosine-protein kinase Mer shows clinical signal disease relevance led by non-small cell lung carcinoma. 1 linked drug keep the rationale reviewable. Linked drugs include NINGETINIB.

Start review with non-small cell lung carcinoma because it currently carries clinical signal support. Linked drugs include NINGETINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 17 approved drugs, 4191 compounds, and 413 assays for this target. The dominant activity type is IC50. CHEMBL5774701 is the current potency anchor at pChEMBL 9.9.

Use CHEMBL5774701 as the tractability anchor when discussing potency (pChEMBL 9.9).

Activity source · ChEMBL 36 via Core Engine
17 approved pChEMBL 9.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Tyrosine-protein kinase Mer matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q12866, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why non-small cell lung carcinoma is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

4191
Total Compounds
413
Total Assays
17
Approved Drugs
IC50: 4148.0, KI: 13.0, EC50: 34.0, KD: 218.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5774701
 9.9 IC50 —
No preferred name
CHEMBL2036807
 9.8 IC50 —
No preferred name
CHEMBL4877347
 9.7 Ki —
No preferred name
CHEMBL2036806
 9.6 IC50 —
No preferred name
CHEMBL1230609
 9.6 Kd Clinical

Approved Drugs

Structure Compound First Approval
FEDRATINIB
CHEMBL1287853
 2019
NERATINIB
CHEMBL180022
 2017
NINTEDANIB
CHEMBL502835
 2014
BOSUTINIB
CHEMBL288441
 2012
CRIZOTINIB
CHEMBL601719
 2011
SUNITINIB
CHEMBL535
 2006
ERLOTINIB
CHEMBL553
 2004
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:04:52Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5331